Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.62 |
| ▸ | APP | P05067 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421838 | 0.96 | AKR1C1 (0.68) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL1807150 | 0.94 | AKR1C1 (0.66) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| Hydrochloric Acid SCHEMBL28577324 | 0.94 | AKR1C1 (0.66) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL301150 | 0.92 | APP (0.61) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL12020347 | 0.84 | HSD11B1 (0.48) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL17761264 | 0.83 | APP (0.54) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL378896 | 0.83 | APP (0.50) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL166581 | 0.83 | APP (0.50) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL5768239 | 0.83 | CYP2C9 (0.50) | AKR1C1APPCYP2C19CYP2C9CYP3A4 | |
| SCHEMBL10002400 | 0.82 | LMNA (0.49) | AKR1C1HSD11B1MEN1KMT2AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200440-B1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | CRESTONE INC (US) | 2017-07-19 | — | — | EP | claimed |
| EP-2200440-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | Crestone, Inc. (US) | 2010-06-30 | — | — | EP | claimed |
| WO-2009015208-A1 | ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS | REPLIDYNE, INC. (US) | 2009-01-29 | — | — | WO | claimed |
| US-20250270202-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2025-08-28 | — | — | US | disclosed |
| EP-4545524-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |
| WO-2023246944-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 中国科学院上海药物研究所 | 2023-12-28 | — | — | WO | disclosed |
| CN-117285524-A | Substituted 4-amino isoindoline compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-12-26 | — | — | CN | disclosed |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| CN-113861071-A | Synthetic method of aryl cyclobutane compound | 上海麦克林生化科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179802-B2 | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO., INC. (US) | 2007-02-20 | — | — | US | disclosed |
| WO-2007006546-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
| CN-1659151-A | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors for the treatment of diabetes, obesity and dyslipidemia | MERCK & CO INC (US) | 2005-08-24 | — | — | CN | disclosed |
| WO-2003104207-A2 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS USEFUL FOR THE TREATMENT OF DIABETES, OBESITY AND DYSLIPIDEMIA | MERCK & CO., INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
| EP-0923536-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | Pharmacia & Upjohn Aktiebolag (SE) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998004517-A1 | ARYLCYCLOALKANE CARBOXYLIC ESTERS, THEIR USE, PHARMACEUTICAL COMPOSITIONS AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-02-05 | — | — | WO | disclosed |
| EP-0001566-A2 | Cyclobutanecarboxylic acid derivatives, processes for their preparation and their use as insecticides | BAYER AG (DE) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270202-A1 | SUBSTITUTED 4-AMINOISOINDOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CUL4B, CUL3, CUL4A | AKR1C1 671/4885APP 1267/4885CYP2C19 880/4885 |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | AKR1C1 277/4885APP 148/4885CYP2C19 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.